Cysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against <i>Leishmania major</i> infection in C57BL/6 mice

Doroud, Delaram; Zahedifard, Farnaz; Vatanara, Alireza; Najafabadi, Abdolhossein Rouholamini; Rafati, Sima

doi:10.1111/j.1365-3024.2011.01289.x

Cited by 35 publications

(13 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They are themselves immunogenic, since L. (L.) mexicana cysteine proteases are T cell immunogen, resulting in the development of potentially protective Thl cell lines. This finding suggests that the cysteine proteases could also be a vaccine candidate and that homologous enzymes in other parasites species may also be so (Khoshgoo et al, 2008;Saffari and Mohabatkar, 2009;Fedelli et al, 2010, Doroud et al, 2011). …”

Section: Cysteine Proteasesmentioning

confidence: 97%

Immunocytochemistry of Proteases in the Study of Leishmania Physiology and Host-Parasite Interaction

Silva-López¹

2012

Applications of Immunocytochemistry

View full text Add to dashboard Cite

Section: Cysteine Proteasesmentioning

confidence: 97%

Immunocytochemistry of Proteases in the Study of Leishmania Physiology and Host-Parasite Interaction

Silva-López¹

2012

Applications of Immunocytochemistry

View full text Add to dashboard Cite

“…96 Another application is vaccine delivery. For example, antigen-loaded solid lipid nanoparticles were efficient in eliciting T H 1 type immune responses and cytokines in mice upon intraperitoneal administration 97 …”

Section: Cytokines As Biomarkers Of Immunomodulatory Properties Ofmentioning

confidence: 99%

Cytokines as biomarkers of nanoparticle immunotoxicity

2013

View full text Add to dashboard Cite

Nanoscale objects, whether of biologic origin or synthetically created, are being developed into devices for a variety of bionanotechnology diagnostic and pharmaceutical applications. However, the potential immunotoxicity of these nanomaterials and mechanisms by which they may induce adverse reactions have not received sufficient attention. Nanomaterials, depending on their characteristics and compositions, can interact with the immune system in several ways and either enhance or suppress immune system function. Cytokines perform pleiotropic functions to mediate and regulate the immune response and are generally recognized as biomarkers of immunotoxicity. While the specificity and validity of certain cytokines as markers of adverse immune response has been established for chemicals, small and macromolecular drugs, research on their applicability for predicting and monitoring the immunotoxicity of engineered nanomaterials is still ongoing. The goal of this review is to provide guidelines as to important cytokines that can be utilized for evaluating the immunotoxicity of nanomaterials and to highlight the role of those cytokines in mediating adverse reactions, which is of particular importance for the clinical development of nanopharmaceuticals and other nanotechnology-based products. Importantly, the rational design of nanomaterials of low immunotoxicity will be discussed, focusing on synthetic nanodevices, with emphasis on both the nanoparticle-forming materials and the embedded cargoes.

show abstract

“…Studies have shown that encapsulation of antigens in liposomes, nanoparticles, or inclusion of adjuvants greatly enhances their immunogenicity and protective ability, [33][34][35] thus underscoring the need for continued studies in improving vaccine delivery. The development of a vaccine will benefit an estimated 350 million people who are at risk of developing the disease worldwide.…”

Section: Opinion: Benefits Of Continued Researchmentioning

confidence: 99%

Social and Economic Burden of Human Leishmaniasis

Okwor¹,

Uzonna²

2016

The American Society of Tropical Medicine and Hygiene

258

163

View full text Add to dashboard Cite

Abstract. Leishmaniasis continues to pose a major public health problem worldwide. With new epidemics occurring in endemic areas and the spread of the disease to previously free areas because of migration, tourism, and military activities, there is a great need for the development of an effective vaccine. Leishmaniasis is a disease of the poor, occurring mostly in remote rural villages with poor housing and little or no access to modern health-care facilities. In endemic areas, diagnosis of any form of leishmaniasis puts a huge financial strain on an already meagre financial resource at both the individual and community levels. Most often families need to sell their assets (land and livestock) or take loans from informal financial outfits with heavy interest rates to pay for the diagnosis and treatment of leishmaniasis. Here, we discuss the disease with special emphasis on its socioeconomic impact on the affected individual and community. In addition, we highlight the reasons why continued research aimed at developing an effective Leishmania vaccine is necessary.

show abstract

Cysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against Leishmania major infection in C57BL/6 mice

Cited by 35 publications

References 30 publications

Immunocytochemistry of Proteases in the Study of Leishmania Physiology and Host-Parasite Interaction

Immunocytochemistry of Proteases in the Study of Leishmania Physiology and Host-Parasite Interaction

Cytokines as biomarkers of nanoparticle immunotoxicity

Social and Economic Burden of Human Leishmaniasis

Contact Info

Product

Resources

About